Publications by authors named "L I F De Ridder"
Background And Aims: Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset < 6 years, can present with severe manifestations and may require biologic therapy. Infliximab and adalimumab are approved for induction and maintenance in pediatric IBD patients but are licensed only above the age of 6 years. Effectiveness and safety data on adalimumab in this patient population are lacking.
View Article and Find Full Text PDFPrimary sclerosing cholangitis in children with inflammatory bowel disease: An ESPGHAN position paper from the Hepatology Committee and the IBD Porto group.
J Pediatr Gastroenterol Nutr
December 2024
Objective: We aimed to provide an evidence-supported approach to diagnose, monitor, and treat children with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC).
Methods: The core group formulated seven PICO-structured clinical questions. A systematic literature search from inception to December 2022 was conducted by a medical librarian using MEDLINE and EMBASE.
Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD.
J Pediatr Gastroenterol Nutr
December 2024
Primary sclerosing cholangitis (PSC) is a risk factor for cholangiocarcinoma. When a child is diagnosed with both PSC and inflammatory bowel disease (IBD), evidence-based information on counseling families and risk management of developing cholangiocarcinoma is limited. In this case series (PubMed/collaborators), we included patients with PSC-IBD who developed cholangiocarcinoma and contacted authors to determine an event curve specifying the time between the second diagnosis (IBD or PSC) and a diagnosis of cholangiocarcinoma.
View Article and Find Full Text PDFGut-homing and intestinal TIGITCD38 memory T cells acquire an IL-12-induced, ex-Th17 pathogenic phenotype in a subgroup of Crohn's disease patients with a severe disease course.
Mucosal Immunol
November 2024
Article Synopsis
- CD4 memory T cell reactivation is linked to chronic inflammatory bowel disease (IBD), affecting conditions like Crohn's disease (CD) and ulcerative colitis, with unclear differences in T cell regulation among patients.
- In a study of pediatric IBD patients, a specific subgroup of therapy-naïve CD patients showed higher frequencies of a particular inflammatory T cell type (TIGITCD38T) associated with severe disease and elevated IFN-γ levels.
- The research identified IL-12 as a key driver of this inflammatory response, with increased IL-12 signaling linked to the transformation of T cells into more pathogenic forms, correlating with worsened intestinal inflammation.